Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7024233 | 0.86 | ADORA2A (0.50) | ADORA2AADORA1KDM4EHSD17B10KMT2A | |
| SCHEMBL7025897 | 0.85 | ADORA2A (0.52) | ADORA2AADORA1LMNAHIF1AKMT2A | |
| SCHEMBL29644283 | 0.83 | MAP2K1 (0.57) | ADORA2AKDM4EKMT2AMEN1MAP2K1 | |
| SCHEMBL26979129 | 0.83 | MAP2K1 (0.57) | ADORA2AKDM4EKMT2AMEN1MAP2K1 | |
| SCHEMBL4239387 | 0.83 | ADORA2A (0.48) | ADORA2AADORA1KDM4EGMNNLMNA | |
| SCHEMBL20769722 | 0.81 | ADORA2A (0.46) | ADORA2ACSNK2A2CSNK2BCSNK2A1ADORA1 | |
| SCHEMBL28089657 | 0.80 | ADORA2A (0.48) | ADORA2AADORA1KMT2AMEN1 | |
| SCHEMBL7099389 | 0.79 | ADORA2A (0.47) | ADORA2AADORA1LMNACYP1A2CYP2C19 | |
| SCHEMBL23749744 | 0.79 | MEN1 (0.58) | ADORA2AADORA1KMT2AMEN1 | |
| SCHEMBL30392836 | 0.79 | MEN1 (0.58) | ADORA2AADORA1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4642764-A2 | AZAINDOLE ROCK INHIBITORS | Avicenna Biosciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12415805-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12286433-B1 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12281115-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12240848-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12116366-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-105777756-A | Heteroaryl compound and application thereof in medicines | 广东东阳光药业有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-8524706-B2 | 1,4-diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| CN-101203518-B | Fluorene derivative, composition containing the same and use thereof | AVENTIS PHARMA SA | 2013-07-24 | — | — | CN | disclosed |
| WO-2011050245-A1 | BICYCLIC HETEROARYLS AS KINASE INHIBITORS | FENG YANGBO (US) | 2011-04-28 | — | — | WO | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20090054416-A1 | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide Derivatives, Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-7456171-B2 | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-11-25 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| CN-101203518-A | Novel fluorene derivatives, compositions containing same and uses thereof | AVENTIS PHARMA SA (FR) | 2008-06-18 | — | — | CN | disclosed |
| US-20050182062-A1 | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415805-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
| US-20090054416-A1 | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide Derivatives, Preparation and Therapeutic Use Thereof | CNR1, CNR2, CACNA1A | ADORA2A 45/4885CSNK2A2 2251/4885CSNK2B 2711/4885 |
| US-12240848-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
| US-20050182062-A1 | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof | CNR1, CNR2, CBR3 | ADORA2A 246/4885CSNK2A2 1570/4885CSNK2B 1644/4885 |
| US-12281115-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | PRKG2, PRKG1, ROCK2 | ADORA2A 1064/4885CSNK2A2 354/4885CSNK2B 411/4885 |
| US-12116366-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
| US-12286433-B1 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | ADORA2A 3575/4885CSNK2A2 136/4885CSNK2B 218/4885 |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | ADORA2A 2996/4885CSNK2A2 1099/4885CSNK2B 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.